FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 03/2022”.
The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector.
As of the end of March 2022, we identify the following current VC trends in the US-Biotech sector:
By Dr. Mathias Schott, Sebastian Sommer and Johannes Link
As of the end of March 2022, we identify the following current VC trends in the US-Biotech sector:
- In 2022, overall Biotech funding in the USA has reached USD 9,341m so far
- Top 5 deals exceed USD 180m each, largest transaction amounted to USD 3,000m in Altos Labs
- Catalio Capital Management (USA) leads the Top 5 Investors (by deal volume), followed by RA Capital Management (USA) and Vida Ventures (USA)
- Central Nervous System dominates as the top indication
By Dr. Mathias Schott, Sebastian Sommer and Johannes Link
Share